Search Results

- Company listed in Research and Markets’ announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - “U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"- -Report supports Company’s regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential for rapid market adoption and significant market share -

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence as an exhibitor at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024.

Aqtual, Inc. announced that it will present a poster at the American Association for Cancer Research Annual Meeting, held April 5-10, 2024, in San Diego, California.

Bio-Techne Corporation announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research, taking place April 5-10, 2024, in San Diego, California.

Indaptus Therapeutics, Inc poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday, April 10th.

Processa Pharmaceuticals, Inc. announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024.

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, from April 5-10, 2024.

Labcorp, a global leader of innovative and comprehensive laboratory services, will present abstracts in the areas of immunology, cellular biology, genomics and liquid biopsy at the Annual Meeting of the American Association for Cancer Research® in San Diego.